Compare SKYW & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYW | DVAX |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 1.3B |
| IPO Year | N/A | 2004 |
| Metric | SKYW | DVAX |
|---|---|---|
| Price | $100.42 | $15.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $124.75 | $26.50 |
| AVG Volume (30 Days) | 276.5K | ★ 3.7M |
| Earning Date | 01-29-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.86 | N/A |
| EPS | ★ 10.47 | N/A |
| Revenue | ★ $3,978,113,000.00 | $330,514,000.00 |
| Revenue This Year | $16.39 | $24.63 |
| Revenue Next Year | $4.36 | $15.85 |
| P/E Ratio | $9.59 | ★ N/A |
| Revenue Growth | 19.27 | ★ 26.73 |
| 52 Week Low | $74.70 | $9.20 |
| 52 Week High | $135.57 | $15.49 |
| Indicator | SKYW | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 88.86 |
| Support Level | $99.97 | $10.78 |
| Resistance Level | $103.02 | $15.43 |
| Average True Range (ATR) | 2.34 | 0.17 |
| MACD | -0.56 | 0.51 |
| Stochastic Oscillator | 6.87 | 97.84 |
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. Generally, SkyWest provides regional flights, and utilizes its smaller, lower-cost aircraft to carry passengers that booked tickets through airlines. It partners with carriers across the world to fly and operate aircraft for a fee. SkyWest may use the carriers's brand and ground support to coordinate marketing and easily transport passengers. The company has two reportable segments: SkyWest Airlines, which generates maximum revenue, and SkyWest Leasing.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.